GI-DLBCL exhibited an increased mutation frequency in TP53, MUC16, CCND3, HIST1H1C, NEB, and ID3 and a reduced mutation frequency in MYD88, CREBBP, BCL2, KMT2D, PIM1, and EZH2. This evidence concerns the gene H1-2 and diffuse large B-cell lymphoma.